Clene Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Clene Inc. (CLNN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $3.00 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2025-03-24
- Clene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $0.29, a 72.12% decline year-over-year.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $1.04.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $3.00.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.25, a 75.96% decline from fiscal 2021.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $1.04, a 10.64% increase from fiscal 2020.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $0.94, a 13.25% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $3.00 10-K · filed 2025-03-24 | |||
| 2024-09-30 | $3.00 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $3.00 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | $0.25 10-K · filed 2023-03-13 | |||
| 2022-09-30 | $0.27 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $0.27 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $0.29 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $1.04 10-K · filed 2022-03-11 | |||
| 2021-09-30 | $1.04 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $0.62 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $1.04 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $0.94 10-K · filed 2021-03-29 | |||
| 2019-12-31 | $0.83 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |